---
document_datetime: 2023-10-31 11:09:09
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/apretude-epar-all-authorised-presentations_en.pdf
document_name: apretude-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 0.9612517
conversion_datetime: 2025-12-18 20:39:54.949576
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
| MA (EU) number   | (Invented) name   | Strength   | Pharmaceutical Form                                           | Route of Administration   | Immediate Packaging   | Content (concentration)   | Pack size   |
|------------------|-------------------|------------|---------------------------------------------------------------|---------------------------|-----------------------|---------------------------|-------------|
| EU/1/23/1760/001 | APRETUDE          | 30 mg      | Film-coated tablet Prolonged-release suspension for injection | Oral use Intramuscular    | bottle (HDPE)         |                           | 30 tablets  |
| EU/1/23/1760/002 | APRETUDE          | 600 mg     |                                                               | use                       | vial (glass)          | 3 ml (200 mg/ml)          | 1 vial      |
| EU/1/23/1760/003 | APRETUDE          | 600 mg     | Prolonged-release suspension for injection                    | Intramuscular use         | vial (glass)          | 3 ml (200 mg/ml)          | 25 vials    |